PROs reveal the patient’s perspective and provide unique information about symptoms and disease impact.1,2 Additionally, physician-derived measures rarely assess factors important to patients, such as sleep, fatigue, psychological well-being, and ability to work.1
Patients with RA can experience barriers to in-person clinic visits due to mobility limitations that can affect driving and walking.3 Fewer in-person visits emphasise the importance of reliable PROs for rheumatology practice as they allow maintenance of tight control of inflammation, potentially limiting RA disease activity and damage and reducing risks associated with inadequately managed disease.4,5
PROs must gather meaningful information from the patient perspective that can be incorporated into clinical practice and inform treatment decisions.6
Access to frequent and reliable information on disease activity, symptoms, and flares is key to maintaining tight control of RA.9,10 Fluctuations in disease activity that can often occur between scheduled clinic visits may be missed by reduced in-person consultation.11
In telemedicine, PROs may help capture past and present flare data to inform the need for patient consultation.2,5
OMERACT Flare Questionnaire2,12
FLARE-RA Questionnaire2,9
RAID Questionnaire13
For more information on RA disease flare management with PROs, consult learnjakstat.com
With telemedicine becoming more common, some traditional disease activity measures are not possible, which emphasises the usefulness of PROs. Digital technology is increasingly present in patients’ daily lives and can be utilised to assess disease activity through ePROs5,9,14,15
The reliance on PROs for patient management has increased due to the circumstances of the COVID-19 pandemic.5
Addressing patient needs beyond physical function and disease activity with PROs
Disease domains important for patient care that may not be adequately addressed by current RA management include1,2:
Additional challenges include:
Patient-Reported Outcomes in RA
Download the patient-reported outcomes infographic.
ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; COVID-19, coronavirus disease 2019; DAS28-ESR/CRP, Disease Activity Score in 28 Joints with Erythrocyte Sedimentation Rate or C-Reactive Protein; ePRO, electronic patient-reported outcome; FLARE-RA, Flare Assessment in Rheumatoid Arthritis; HAQ-II, Health Assessment Questionnaire II; HRQoL, health-related quality of life; MDHAQ, Multidimensional Health Assessment Questionnaire; OMERACT, Outcome Measures in Rheumatoid Arthritis Clinical Trials; PAS-II, Patient Activity Scale II; PRO, patient-reported outcome; PROMIS PF10a, Patient-Reported Outcome Measurement Information System Physical Function 10-Item short form; RA, rheumatoid arthritis; RAPID3, Routine Assessment of Patient Index Data 3; SDAI, Simplified Disease Activity Index.
REFERENCES
1. Gossec L, Dougados M, Dixon W. RMD Open. 2015;1(1):e000019. 2. Fautrel B, Alten R, Kirkham B, et al. Rheumatol Int. 2018;38(6):935-947. 3. InformedHealth.org [Internet]. Everyday life with rheumatoid arthritis. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. Updated May 20, 2020. Accessed March 31, 2021. https://www.ncbi.nlm.nih.gov/books/NBK384458/ 4. Grigor C, Capell H, Stirling A, et al. Lancet. 2004;364(9430):263-269. 5. Taylor PC. Nat Rev Rheumatol. 2020;16(9):477-478. 6. Jagpal A, O’Beirne R, Morris MS, et al. BMC Rheumatol. 2019;3:36. 7. England BR, Tiong BK, Bergman MJ, et al. Arthritis Care Res (Hoboken). 2019;71(12):1540-1555. 8. Barber CEH, Zell J, Yazdany J, et al. Arthritis Care Res (Hoboken). 2019;71(12):1531-1539. 9. de Thurah A, Stengaard-Pedersen K, Axelsen M, et al. Arthritis Care Res (Hoboken). 2018;70(3):353-360. 10. Say P, Stein DM, Ancker JS, Hsieh C-K, Pollak JP, Estrin D. AMIA Annu Symp Proc. 2015;2015:1130-1139. 11. Nowell WB, Curtis JR, Nolot SK, et al. JMIR Res Protoc. 2019;8(9):e14665. 12. Bykerk VP, Bingham CO, Choy EH, et al. RMD Open. 2016;2(1):e000225. 13. Santos EJF, Duarte C, da Silva JAP, Ferreira RJO. Rheumatology (Oxford). 2019;58(Suppl 5):v3-v9. 14. Mobile fact sheet. Pew Research Center. June 12, 2019. Accessed March 12, 2021. http://www.pewresearch.org/internet/fact-sheet/mobile/ 15. Vogels EA. About one-in-five Americans use a smart watch or fitness tracker. Pew Research Center. January 9, 2020. Accessed March 12, 2021. http://www.pewresearch.org/fact-tank/2020/01/09/about-one-in-five-americans-use-a-smart-watch-or-fitness-tracker/ 16. Bingham CO 3rd, Gaich CL, Engstrom KD, et al. Trials. 2019;20(1):182.
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos
NV.
© Galapagos Biopharma Sweden AB.
Vasagatan 7, 101 23 Stockholm, Sweden, VAT: SE559311454801. All rights reserved.
SE-RA-JY-202203-00001
© Copyright 2021 Galapagos NV
You are about to leave this website and will be redirected to an external website. We are not responsible of that external website’s content. By continuing, you confirm that you have taken note of this.